ONCR-177, our lead candidate, is an intratumorally administered oncolytic Herpes Simplex Virus-1 (HSV-1) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4).

Learn more about our HSV-1 Platform

Preclinical Findings

In preclinical studies, we have observed durable virus and immune system-driven anti-tumor activity in injected tumors as well as abscopal activity.  We have also observed that ONCR-177 is well tolerated in a validated animal safety model of HSV-1 when administered intravenously.

Learn more about our preclinical findings

Development Status

We are currently enrolling patients in a Phase 1, open-label, multi-center study of ONCR-177 alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors (ClinicalTrials.gov Identifier: NCT04348916).  The purpose of the study is to assess the safety and tolerability of ONCR-177 alone and in combination with PD-1 blockade and to determine the maximum tolerated dose and recommended Phase 2 dose, as well as to evaluate preliminary efficacy.

For more information, please visit: https://clinicaltrials.gov/ct2/show/NCT04348916

Our lead synthetic viral immunotherapy program is based on the coxsackievirus A21 (CVA21). We selected to advance a CVA21 product candidate based on a number of properties, including:

• Demonstrated safety and tolerability after intravenous (IV) administration in patients
• Ability to replicate in solid tumors, including lung tumors
• Inability to insert into host chromosome, eliminating the potential of insertional mutagenesis

Learn more about our Synthetic Virus Platform, including our novel liquid nanoparticle (LNP) delivery strategy designed to overcome the challenges caused by neutralizing antibodies that have limited the efficacy of previous industry efforts to a treat tumors utilizing IV administration of CVA21. 

Development Status

In preclinical models, we have demonstrated proof of concept that our coxsackievirus A21 (CVA21)-based viral immunotherapy, when administered intravenously, is able to successfully deliver a synthetic viral genome to tumors leading to production of a replication-competent virus within the tumors that cause tumor growth inhibition.

We continue to conduct preclinical studies of our Synthetic Virus Platform and advance our lead Synthetic CVA21 clinical candidate toward the clinic.

We are advancing a Seneca Valley Virus (SVV)-based synthetic virus program based on the acceptable safety and tolerability demonstrated by the intravenous (IV) administration of this virus in previously conducted early clinical trials.

Learn more about our Synthetic Virus Platform.

Our SVV-based viral immunotherapy program will utilize shared formulation and manufacturing strategies with our lead synthetic viral immunotherapy candidate (coxsackievirus A21, or CVA21, program) enabling efficiencies in product candidate development.

Development Status

In preclinical models, we have demonstrated proof of concept that our SVV-based viral immunotherapy, when administered intravenously, is able to successfully deliver a synthetic viral genome to tumors leading to production of a replication-competent virus within the tumors that cause tumor growth inhibition.

We continue to conduct preclinical studies of our SVV program.